Biosimilar Development Meetings At US FDA Not Just For Talking Similarity

 
• By Sue Sutter

Sponsors shouldn't wait until pre-submission meetings with the agency to discuss manufacturing, packaging and other matters unrelated to similarity data, FDA's Leah Christl says in remarks seemingly aimed at calling attention to issues that can forestall approval.

Woman listens
US FDA is listening when biosimilar sponsors raise manufacturing and other issues during product development meetings.

More from Biosimilars

More from Biosimilars & Generics